Penalized by a disappointing fourth quarter, the Tunisian pharmaceutical industry Company (SIPHAT) saw its annual turnover fall by 18% to 7.7 million dinars in 2024, compared with 9.5 million dinars in 2023.
Sales in the fourth quarter of 2024 were 42% lower than in 2023, due to a 95% drop in sales of prescription drugs.
In addition, SIPHAT did not generate any export sales in 2024, including the paramedical form.
On the other hand, SIPHAT’s production (in value terms) increased slightly in 2024, from 7.5 million dinars to 7.7 million dinars, an increase of around 2%.
The main black mark on the company’s balance sheet, outstanding debts, continued to rise, reaching 128.5 million dinars at the end of December last year, compared with 108.2 million dinars a year earlier, an increase of 18.8%.
